Schrezenmeier et al., 2019 - Google Patents
S863 ONE-YEAR EFFICACY OF RAVULIZUMAB (ALXN1210) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO …Schrezenmeier et al., 2019
View PDF- Document ID
- 17755067823040204631
- Author
- Schrezenmeier H
- Kulasekararaj A
- Mitchell L
- de Fontbrune F
- Devo T
- Okamoto S
- Wells R
- Rottinghaus S
- Liu P
- Ortiz S
- Shafner L
- Lee J
- Socie G
- Publication year
- Publication venue
- HemaSphere
External Links
Snippet
Background: Ravulizumab, a novel C5 complement inhibitor, was approved by FDA for treating paroxysmal nocturnal hemoglobinuria (PNH) and is under review in EMEA and Japan. In the largest phase 3 study in complement inhibitor-naive PNH patients (pts) …
- 108010090937 ravulizumab 0 title abstract description 41
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haldar et al. | Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages | |
| Stanley et al. | Recent advances in understanding clonal haematopoiesis in aplastic anaemia | |
| Wang et al. | Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity | |
| All-Ericsson et al. | c-Kit–dependent growth of uveal melanoma cells: a potential therapeutic target? | |
| Alam et al. | Counter regulation of spic by NF-κB and STAT signaling controls inflammation and iron metabolism in macrophages | |
| Li et al. | Identification of a novel partner gene, TPR, fused to FGFR1 in 8p11 myeloproliferative syndrome | |
| CA2983004A1 (en) | Methods for treating myeloproliferative disorders | |
| US20090191185A1 (en) | Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling | |
| US20230046656A1 (en) | Crebbp related cancer therapy | |
| CN113382728A (en) | Age-related clonal hematopoiesis and prevention of diseases related to the same | |
| EP3601535A1 (en) | Natural killer cells | |
| McAvoy et al. | Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo | |
| Ritchey et al. | Genetic variant in 3’untranslated region of the mouse pycard gene regulates inflammasome activity | |
| Imtiyaz et al. | The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation | |
| Duan et al. | USP3 plays a critical role in the induction of innate immune tolerance | |
| Schrezenmeier et al. | S863 ONE-YEAR EFFICACY OF RAVULIZUMAB (ALXN1210) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAIVE TO COMPLEMENT INHIBITORS | |
| Koyunlar et al. | S862 THE ROLE OF GATA2 IN HSC GENERATION THROUGH ENDOTHELIAL-TO-HEMATOPOIETIC TRANSITION. | |
| Li et al. | Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas | |
| WO2022031859A2 (en) | Methylmalonic acid and metabolism thereof is a cancer biomarker and target | |
| Fettucciari et al. | Macrophage induced gelsolin in response to Group BS treptococcus (GBS) infection | |
| CN114555636A (en) | Monoclonal antibody or antibody fragment against canine CD20 | |
| Kreutmair et al. | S861 LOSS OF THE F-BOX PROTEIN NIPA CAUSES BONE MARROW FAILURE | |
| JP7538798B2 (en) | Phosphorylated Dicer Antibodies and Methods of Use Thereof | |
| Lossos | Harnessing the tumor microenvironment for the treatment of double hit lymphoma | |
| Thenoz et al. | S860 TARGETING ABERRANT DNA METHYLATION AS A NOVEL AND UNIFORM THERAPEUTIC STRATEGY FOR THE TREATMENT OF T‐CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA |